Risk Clinical Trials

596 recruitingLast updated: July 25, 2026

There are 596 actively recruiting risk clinical trials across 76 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Risk Trials at a Glance

596 actively recruiting trials for risk are listed on ClinicalTrialsFinder across 6 cities in 76 countries. The largest study group is Not Applicable with 236 trials, with the heaviest enrollment activity in New York, Boston, and Houston. Lead sponsors running risk studies include M.D. Anderson Cancer Center, Ohio State University, and IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Treatments under study

About Risk Clinical Trials

Looking for clinical trials for Risk? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Risk trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Risk clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 596 trials

Recruiting
Not Applicable

Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer

Cervical Cancer ScreeningHPV InfectionHPV+8 more
Qurasense450 enrolled3 locationsNCT07281599
Recruiting
Not Applicable

BRAVE Program to Improve Safety and Reduce Violence Risk in Early Psychosis

Early PsychosisViolence Risk
Howard University30 enrolled2 locationsNCT07417904
Recruiting
Not Applicable

BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

High Risk Smoldering Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT06745687
Recruiting
Phase 2

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

NeuroblastomaHigh Risk NeuroblastomaChildhood Neuroblastoma
Memorial Sloan Kettering Cancer Center45 enrolled1 locationNCT06528496
Recruiting

Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity

Obesity and OverweightWeight LossWeight Management+2 more
John Bauer50 enrolled1 locationNCT06967389
Recruiting
Not Applicable

Determining Efficacy of an Artificial Intelligence-based System for Heart Failure Detection Through Interpretation of Electrocardiograms (DECISION)

Heart FailureCardiovascular Risk Factors
Idoven 1903 S.L.1,968 enrolled5 locationsNCT07113223
Recruiting
Phase 3

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

High-risk Muscle Invasive Urothelial Carcinoma
AstraZeneca915 enrolled160 locationsNCT07720284
Recruiting
Not Applicable

Effectiveness of a Self-health Assessment Mobile Application in Young-to-midlife Adults in Hong Kong

Diabetes riskColorectal, CancerLung Cancer+2 more
The University of Hong Kong574 enrolled1 locationNCT07720245
Recruiting
Phase 3

PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

Coronary Artery Disease ProgressionPremature AtherosclerosisCoronary Artery Disease Risk Factors Multiple+1 more
Duke University1,500 enrolled23 locationsNCT07232069
Recruiting

Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform

High-risk Cardiac Patients
Idoven 1903 S.L.200,000 enrolled5 locationsNCT07333547
Recruiting
Phase 1Phase 2

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Acute Lymphoblastic LeukaemiaHigher Risk Myelodysplastic SyndromesAcute Myeloid Leukaemia
AstraZeneca84 enrolled30 locationsNCT07155226
Recruiting

Testing Warning Labels for Retail Cannabis Products Using a Discrete Choice Experiment

Risk perceptionDecision MakingCannabis Use
University of Oklahoma450 enrolled1 locationNCT07701304
Recruiting
Phase 2

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Multiple MyelomaSmoldering Multiple MyelomaHigh Risk Smoldering Multiple Myeloma
Irene Ghobrial, MD52 enrolled3 locationsNCT05469893
Recruiting

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

Vitamin K-Dependent Coagulation DefectSignificant Bleeding Risk
Octapharma3,574 enrolled1 locationNCT06429787
Recruiting

Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women

Cardiovascular (CV) Risk
National Heart, Lung, and Blood Institute (NHLBI)250 enrolled1 locationNCT04014348
Recruiting
Not Applicable

Cardiometabolic Risk in Pregnancy and Postpartum

Hypertensive Disorders of PregnancyHigh Blood PressureCardiovascular Disease Risk+1 more
Forgive Avorgbedor200 enrolled1 locationNCT07420465
Recruiting
Not Applicable

ELEVATE High-Risk PCI Pivotal Study

High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Magenta Medical Ltd.290 enrolled33 locationsNCT07001332
Recruiting
Phase 2

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

HER2-negative Breast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)Hormone Receptor-Positive Breast Cancer+3 more
Peking University People's Hospital393 enrolled1 locationNCT06970912
Recruiting
Early Phase 1

CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms

High-risk Plasma Cell Neoplasms
Affiliated Hospital to Academy of Military Medical Sciences20 enrolled1 locationNCT07416682
Recruiting
Phase 3

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled995 locationsNCT07181109